Conclusion: Atorvastatin with far-infrared radiation therapy via reducing inflammatory factors and thrombosis factors to protect AVF and deserve to be widely used in clinic.
Objective: To understand the status of clinical features and pathogenic bacteria by analyzed the related factor, in order to improve the patients' quality of life. Methods: Selected the patients from January 2012 to December 2014, and recorded each patient's gender, age, primary disease, intestinal disorders (diarrhea or constipation), peritoneal fluid culture, serum albumin, hemoglobin, serum creatinine, serum calcium, serum phosphorus, parathyroid hormone, peritoneal dialysis age. Summed up the pathogenic bacteria, clarify the dangerous factors of PD related peritonitis. Results: (1) There were 46 cases including 58 times of PD related peritonitis in total of 126 cases, and 47 cases culture positive in the 58 times of peritoneal fluid culture, the positive rate was 81.03%, including 29 cases with Gram-positive cocci (61.70%), Gram-negative bacilli in 12 cases (25.53%), 6 cases of fungus (12.76%). (2) There was no difference between the two group of patients' age, gender, dialysis age and primary disease. (3) Peritonitis patients' red blood cell, hemoglobin, serum albumin, serum calcium levels were lower than the control group (P < 0.05). (4) Peritonitis group diarrhea/constipation increased significantly compared with the control group (P < 0.01). (5) Peritonitis group of 58 patients with a total of three deaths, 6 cases changed to hemodialysis, the rest of the patients were cured. The 6 cases of fungal peritonitis, 4 cases had extubation and changed hemodialysis, 2 cases died. Conclusion: (1) Gram-positive bacteria are the most common pathogens in PD-related peritonitis. (2) Poor nutrition, anemia, electrolyte disorder, bowel dysfunction are the risk factor of PD-related peritonitis. (3) Fungal peritonitis had a higher rate of mortality and dropout rates. Objective: Explore the efficacy of Long-term catheter maintenance in uremia patients with regular thrombolysis therapy by urokinase. Methods: Forty uremia patients were recruited from our hospital between October 2008 and December 2014. They were all received blood purification average from 3 to 6 years. All of them were cuff tube. 21 patients were male, average age, 68.40. They were divided into two groups randomly: group A (19 cases), they were treated with thrombolysis therapy by urokinase after dialysis. These patients received thrombolysis therapy by urokinase regularly (once every 2 weeks), sealed with heparin when blood purification were ended. And control group (21 cases) only treated with heparin sealing. Then compare the index changes, such as Bun, Scr, KT/v, PT, APTT. Results: Compared blood flow, venous pressure, Bun, Scr, PT and APTT of the two group patients before treatment. There were no statistically significant differences (all P > 0.05). The levels of venous pressure of urokinase intervention group on a regular basis was 68 AE 30.5 mmHg, BUN (7.2 AE 3.7 mmol/ l), Scr (200.5 AE 90.4 umol/l), there were statistically significant difference (all P < 0.05). CRP obviously reduced after the intervention compared with control group; the blood flow and KT/v obviously increased, there were statistically significant differences (all P < 0.05). There were no statistically significant differences (all P > 0.05) of PT and APTT. There were 2 cases in the group thrombolysis therapy by urokinase, accounting for 11%. Ten people in the control group, accounting for 47%. There were no statistically significant differences (P > 0.05) of bleeding. Objective: To elucidate the effects of serum of patients with hemodialysis on tissue factor (TF) and plasminogen activator inhibitor-1 (PAl-1) secretion of human vascular endothelial cells (HUVEC) during treat of atorvastatin and anticoagulant. Methods: Twenty patients who snuffbox arteriovenous fistula (SAV) or central venous catheterization in hemodialysis patients involved were divided into two groups randomly, 10 patients treated with atorvastatin and anticoagulant and the others with anticoagulant for 3 months. The blood was collected from patients at 0 months, 1 month, 2 months, and 3 months during treatment. Serum TNF-a, IL-1b were measured by ELlSA. TF and PAl-1 secretion of HUVEC stimulated with serum of patients with hemodialysis undergoing drug treatment were detected. TF and PAl-1 expression level were assayed by RT-PCR. Results: TF and PAl-1 secretion were significantly increased in HUVEC stimulated with serum of patients with haemodialysis, but the levels were decreased after treatment with atorvastatin and anticoagulant. The secretion of TNF-a and IL-1b that atorvastatin and anticoagulant group were lower than atorvastatin group. Conclusion: Serum of patients with hemodialysis promote the secretion of TF and PAI-1 in HUVEC. The dysfunction of HUVEC induced by serum of patients with hemodialysis may be related to mediators of inflammation. Treat S134 Dialysis
